Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Stifel Nicolaus

Equities research analysts at Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $47.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 92.23% from the stock’s previous close.

Bicara Therapeutics Stock Down 2.8 %

Bicara Therapeutics stock opened at $24.45 on Tuesday. Bicara Therapeutics has a 12 month low of $21.05 and a 12 month high of $27.94.

Insider Activity at Bicara Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the stock in a transaction dated Monday, September 16th. The shares were purchased at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the stock in a transaction dated Monday, September 16th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were bought at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the completion of the acquisition, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.